Usmani discussed the common adverse events observed from CARTITUDE-1, including hematologic events and cytokine release syndrome.
Saad Z. Usmani, MD, MBA, FACP
Advertisement
Articles by Saad Z. Usmani, MD, MBA, FACP
Usmani noted the strong overall response and stringent complete response rates observed with ciltacabtagene autoleucel for multiple myeloma at a median follow-up of 18 months.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Emerging Strategies in Prostate Cancer: Molecular Glues and T-Cell Engagers
2
BCMA-Directed Bispecific Antibodies Navigating a New Era in Relapsed/Refractory Multiple Myeloma
3
What’s The State of Immunotherapy, Transplantation in Hematologic Oncology?
4
Novel Immunotherapy Reduces Breast Recurrence Rates in Non-HLA-A*02 Population
5